I wouldn't claim to know any more about what's going to
I wouldn't claim to know any more about what's going to happen on Wednesday's call than anyone else. I bought in around February of 2019 and have continued to increase my shares with the exception of a small amount I sold to cover the cost of some home renovations. I'm up a good bit. Even after the great bull*$#& collapse from $10 to $3-ish, because I'm an expert investor*.
*Not true about being an expert, just lucky I think
So what do I think is going to happen on the call Wednesday? Great question and thank you so much for asking me...
Details of the current discussions with MHRA in regards to fast track approval for COVID-19
Would it be written that way if the MHRA had already told us to bugger off?
(Please award me appropriate points for using "bugger", which I'm only 85% sure is a term used in the UK. Bollocks if not.)
I still think this is the best possible route to revenue at this moment. They developed NEWS2 and we crushed it. They also have a good bit of Covid still. I'm no mathematishionist* but that adds up to a win in my book. I'll also wager that they're at least a little less corrupt than the FDA and can see a f*$&ing gift horse when it presents itself. Also don't sleep in Israel. They wouldn't normally be in the top 5 of countries approached so there are reasons and relationships driving that which can make all the difference.
*Medical term
Status of Emergency Use Approval for COVID-19, CD10 trial in U.S.
I believe this portion of the call will go like this:
NP: The FDA has been amazing so far and they have asked us for some data around the trial that we are providing by sometime next week. After we submit that data we expect feedback within 1-2 weeks and we are thankful for the (corrupt and pathetic*) FDA's efforts in helping bring this important product to market. Can-kicking down the road in other words.
*My words, but I think we an all agree that there's some shenanigans occurring right now within the FDA
Detail discussions of the cancer results and discussions from invited guest (from Creative MicroTech) on the leronlimab potential in all cancers based on current results in the last 1 year
This is actually pretty exciting. Aren't we awaiting a breakthrough designation on the basket cancers? They, meaning Creative MicroTech, have apparently been involved for a little while now and if patients are continuing to end up with 0 circulating tumor cells than watch out!
HIV – BLA submission in U.S. and U.K.
Spoiler alert because Cytodyn wants it and they've asked for it and they've not been responded to yet. At least in the US. Try to keep it in your pants as we don't get any substantial news on this front from the states. But maybe we get a nugget or two from the UK. I mean, for crying out loud the evidence is substantial at this point. We just need someone who isn't "conflicted" to look at it.
HIV – cure project
How great would it be if they've already injected a few patients?! I know this kind of trial depends on when they're scheduled for their transplant but I have to imagine this makes all the news sites if it's successful so I'm anxious to see it get underway.
NASH timeline
I think they're finally ready to start really sinking money into this. Sucks that a fully funded, revenue generating company would have probably been further along but we aren't here to turn a $79/share stock into $94. We're trying to usher this "penny" OTC stock into the stratosphere for a much greater return. Dem's the breaks.
Potential other trials
Clearly it's not anything of substance if we're just talking "potential". I'd love an MS or Alzheimer's trial as much as the next guy but I'm banking on the fact that these sorts of things are too fringe to be happening any time soon.
Scientific Advisory Board
Wait! We have a science board?! I had no idea!!!
Kidding, of course. This is a tremendous idea that will pay off significantly over time. I can't imagine there's any meat on this bone right now though,as they just started announcing people. I'm guessing we just added another one or two people at this point.
NASDAQ uplist
People really have their you know what's in a wad over this. Nasdaq folks appear to be behind their traditional timelines right now. But even then they explain publicly that the time for the company to respond to questions is a 1-2 week process and the time that NASDAQ takes to process that information is another 1-2 weeks. So we are well within that timeframe and looking at another week or so before we can reasonably expect an answer without any other variables getting involved.
But here's the thing. We qualify. There's no reason we shouldn't be accepted. Same for HIV BLA. We qualify. There's no real reason we shouldn't be accepted.
When it comes to Covid I'm as annoyed as the rest of you about exposure but consider that almost nobody posting about Covid treatments is really an expert about what's going on. If you start googling monoclonal antibodies you will find a lot of information about everything but Leronlimab. Hell, even stat news has an article on the first page because they understand how to abuse the system and show up in searches. People who do the laziest of DD will not easily find Cytodyn or learn much of substance about Leronlimab. It perpetuates itself.
The MINUTE we get an authorization in another country (which is my prediction for how it will go, by the way) we will be contracting with them to sell over 1 BILLION DOLLARS in inventory. That's all we need. The media will follow. The share price will rise. The approvals will follow. The share price will rise. The reserving/purchase of 2021's stock will happen and that will be far more than 1 Billion dollars. The share price will rise. The agreements to increase production will happen. Me spending an absurd amount of money on a bottle of wine to celebrate will happen. Gloating to AF on twitter and calling him a failed Dbag will happen. You get the point. I'll be drunk and pretending like I knew all along exactly how it would go while conveniently forgetting that I predicted we'd be at $20+ weeks ago.
Long. Strong. And about to get the friction on.
47
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Bold Step in Healthcare Coordination No doubt about it, healthcare is a mess. It's like trying to patch a leaking ship with duct tape—point solutions here, add-ons there, and nothing truly working in harmony. And in storms in Lyric Health, claiming they've got the answer. They've launched an AI-powered Healthcare Operating System meant to unify these disjointed pieces...
Continue Reading
Hold onto your hats, folks—Propensity just blasted its way to Number 70 on the Inc. 5000 for 2026. That's quite a leap from the 2,591 spot just last year. If you're scratching your head wondering what's behind this meteoric rise, it’s all about AI and knowing which buyer signals really matter. The AI Advantage in B2B The B2B marketing space isn't exactly the new Wild...
Continue Reading
The Honoring of Leadership That Goes Beyond Business In a world where financial influence often feels like it funnels into the same familiar pockets, the news of Jacob Walthour Jr.'s upcoming recognition feels like a fresh breeze of change. The Alpha Phi Alpha's Alpha Alpha Lambda Chapter is rolling out the red carpet at its Centennial Gala for Walthour, throwing him into...
Continue Reading
Fences Go Solar: Welcome to the Future Land of fences and sunshine, North Texas is about to see a game changer in home improvement. Southwest Fence & Deck is rolling out the red carpet as an Authorized SOL Fence Installation Partner, putting solar power right in your backyard. Yeah, there have been sparks of innovation in plenty of fields, but who expected fences to join...
Continue Reading
Medicare's New Program: Potential Knockout Punch? Today, we dive into Medicare's latest shake-up that might just be the unseen wrecking ball swinging toward thousands of jobs and small businesses in the healthcare sector. Two years from now, starting January 2028, the Competitive Bidding Program is set to reroute the entire landscape for suppliers of key medical products...
Continue Reading
Finastra Steals the Spotlight in Payments Innovation When it comes to the modern world of finance, nothing screams ‘adapt or fade into oblivion’ like the payments industry. Well, here’s a reality check from QKS Group: Finastra has snatched the spotlight in their SPARK Matrix™ for 2026 as a powerhouse in integrated bank payments platforms. Clearly, this ain’t...
Continue Reading
Cyber Costs Skyrocket in Latest Study NetDiligence’s 2026 Cyber Claims Study isn't just another report—it’s a wake-up call. The numbers paint a stark picture: cyber incidents are burning deeper holes in pockets, and no one's immune. Whether you're a scrappy SME or a lumbering corporate giant, this report puts a magnifying glass to the chilling reality of cyber...
Continue Reading
A Big Day for American Savings Bank Buckled up yet? Because American Savings Bank has just shot onto the NYSE, raising a hefty $129 million. A solid start, I’d say, for a Honolulu-based outfit that now struts around with a valuation tipping beyond $1.03 billion. That’s what you get when you price more than eight million shares at $16 a pop. NYSE:ASBH is the new kid on...
Continue Reading
A Strategic Alignment Unfolds in Environmental Engineering Ever notice how those industry shifts often sneak up on you, only to leave a mark that's hard to ignore? That's exactly what's playing out with Koogler & Associates' recent hookup with ALL4 LLC. Set aside that coffee, this one's too important to miss if you've got a stake in the environmental consulting game or...
Continue Reading
Clear Stories, Stronger Growth If companies can't tell a clear story that their buyers understand and believe, they're destined to stagnate. That's the blunt reality kompeld is pushing with their H2 2026 Narrative Coherence Benchmark. The report scores 150 B2B tech companies on their narrative coherence, showing there's a stark correlation between storytelling and growth....
Continue Reading
Top 5 Most Recently Viewed Articles
Stefan Szanto Elevated to New Role at Education Growth Partners Education Growth Partners (EGP), a renowned private equity firm based in Stamford, Connecticut, is excited to share significant news about the promotion of Stefan Szanto to the position of Partner. This move reflects not only EGP's commitment to developing talent but also highlights Stefan’s remarkable...
Continue Reading
Philippine Central Bank Reduces Policy Rate The Philippine central bank recently announced a significant move in its monetary policy by cutting the key interest rate by 25 basis points, bringing it down to a comfortable 6.0%. This decision was anticipated, aligning with expectations set by various economists. Reasons Behind the Rate Reduction The Governor of Bangko...
Continue Reading
AmpliTech Group Welcomes Aamir Sultan to Its Advisory Board AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), based in Hauppauge, New York, is excited to announce the addition of Aamir Sultan to its Board of Advisors. With a strong background in technology and government affairs, Mr. Sultan's appointment is expected to enhance the company’s strategic growth across various...
Continue Reading
Welltower to Participate in Global Real Estate Conference Welltower Inc. has announced that its Chief Executive Officer, Shankh Mitra, will be attending an important event in the real estate industry. He is set to take part in a panel discussion at the upcoming conference dedicated to global real estate. This panel will occur in the mid-afternoon, offering attendees...
Continue Reading
Michael Baker International Announces Leadership Change Michael Baker International has taken an exciting step as it promotes William Neider, P.E., to the role of National Mining and Reclamation Practice Manager. This appointment signifies a strong commitment to advancing their initiatives in abandoned mine reclamation across the nation. William Neider’s Expertise in...
Continue Reading